Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model

McEwan P, Kim R, Yuan Y

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1007/s40258-012-0002-0

Indexing Status
Subject indexing assigned by NLM

MeSH
Antiviral Agents /economics /therapeutic use; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Great Britain; Hepacivirus /genetics; Hepatitis C, Chronic /drug therapy /virology; Humans; Interferon-alpha /economics /therapeutic use; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols /economics /therapeutic use; RNA, Viral; Recombinant Proteins /economics /therapeutic use; Ribavirin /economics /therapeutic use

AccessionNumber
22013010496

Date bibliographic record published
29/04/2014